Literature DB >> 8592804

Phenotypic analysis of neoplastic cells from calf, thymic, and intermediate forms of bovine leukosis.

M Asahina1, K Kimura, K Murakami, T Ajito, D Wu, M Goryo, Y Aida, W C Davis, K Okada.   

Abstract

Immunohistochemistry and flow cytometric analysis were used with monoclonal antibodies to examine the phenotype of neoplastic cells from cattle with sporadic bovine leukosis (three cases of calf form, two cases of thymic form, and three cases of intermediate form). Three cases of calf form and two cases of intermediate form were positive for B cell lineage in immunohistologic examination and in flow cytometric analysis for B-B2+, sIgM+, and major histocompatibility class II+. Two cases of thymic form and one case of intermediate form were CD2+, CD5+, CD6+, and CD8+ in immunohistologic examination and in flow cytometric analysis. The results show that neoplastic cells develop from B and T cell lineages in sporadic bovine leukosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592804     DOI: 10.1177/030098589503200610

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  3 in total

1.  Establishment of a simplified inverse polymerase chain reaction method for diagnosis of enzootic bovine leukosis.

Authors:  Asami Nishimori; Kiyohiko Andoh; Yuichi Matsuura; Asuka Kumagai; Shinichi Hatama
Journal:  Arch Virol       Date:  2021-01-24       Impact factor: 2.574

2.  Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis.

Authors:  Asami Nishimori; Satoru Konnai; Tomohiro Okagawa; Naoya Maekawa; Shinya Goto; Ryoyo Ikebuchi; Ayako Nakahara; Yuzumi Chiba; Masaho Ikeda; Shiro Murata; Kazuhiko Ohashi
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

3.  Atypical sporadic lymphosarcoma in a 7-month-old Holstein heifer.

Authors:  P Dubreuil; A Lanevschi; M A Perrone; M Desnoyers
Journal:  Can Vet J       Date:  1998-07       Impact factor: 1.008

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.